Member Info for Yorkshirepragma

https://www.biopharmadive.com/news/amgen-horizon-acquire-biotech-drug-deal/638485/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202022-12-12%20Breaking%20News:%20BioPharma%20%5Bissue:46618%5D&utm_term=BioPharma%20Dive

ES, well said…

“To completely change something so it is much better”. Interesting choice of words for succinct scientists .
GLA

Patience is a virtue, and the brave patients participating Nate virtuous . God bless them.

https://pages.pharmaintelligence.informa.com/JPMorgan-2023-Daily-Updates-Form?src=biopharm

UPcoming :- Data + Takeda support …?
GLA

“The FDA can grant an ODD based upon review of preclinical data” , not quite QED but good enough!
GLA

During dose escalation ,the efficacy of release will have been assessed ,ie drug in/out data and available biopsy ,other evaluation.
Escalation would not have proceeded without pos. direction.
GLA

https://www.statista.com/statistics/1028311/price-earnings-in-the-health-and-pharmaceuticals-sector-in-europe/

But good when it goes well…
GLA

https://www.nature.com/articles/s41587-022-01529-2/figures/1

The potential to give a kinder treatment .

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000168/

2nd day? Does this perhaps reflect Stateside interest?

Great sentiment, here’s hoping it succeeds
GLA

You get the jist, I blame the Pinot noir. But comms t given in good faith through pals/ links/ in the pharms sector.
Regards

Word is M&Zack uptick is now “occurring” for several reasons ,but primarily catch up with business strategic catch up post covid etc. So a potential race on , to sweep up before it’s too late .
Gla

Prediction: On positive RNS $1-2bn mcap , with publicity and “ interest 2-3, thereafter?
GLA

17/11 II update ….stand by

Gmcc, apocryphal perhaps… as a former pharma bod I agree with your pal, as does Susquehanna ….
Potentially a several $bn cap on a following wind…
GLA

Licensing will be the answer here…GLA news domani

As subjects tbc have been resented already in briefs , it’s liklet new information suitably caveated of course....
GLA